Effect of luteolin on gene expression in mouse H22 hepatoma cells

J.X. Niu¹, H.P. Guo², H.M. Gan³, L.D. Bao⁴, J.J. Ren¹

¹Department of General Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
²Department of Physical Examination, Binzhou People’s Hospital, Shandong, China
³Intensive Care Unit, Binzhou People’s Hospital, Shandong, China
⁴Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China

Corresponding authors: J.J. Ren / L.D. Bao
E-mail: renjianjun237@163.com / Baolidao237@qq.com

Received June 3, 2015
Accepted September 8, 2015
Published November 18, 2015
DOI http://dx.doi.org/10.4238/2015.November.18.7

ABSTRACT. The purpose of our study was to observe the effects of luteolin on the expression of the genes ICAM-1, LFA-3, and PCNA in H22 hepatoma tissue. Sixty ICR (Institute of Cancer Research) mice with H22 hepatoma were randomly divided into five groups: a normal saline control group, low-, medium-, and high-dose luteolin groups, and a cyclophosphamide group. The mice were euthanized the day after administration withdrawal and subcutaneous tumor tissue was extracted. Quantitative fluorescence RT-PCR was used to detect the expression of ICAM-1, LFA-3, and PCNA in H22 hepatoma tissue in the mice. Luteolin was found to up-regulate the expression of ICAM-1 in H22 hepatoma tissue, of which the middle-dose group had the most obvious effect, showing a significant difference (P < 0.01) as compared to the normal saline group. Each dose group of luteolin significantly
down-regulated the expression of LFA-3 in H22 hepatoma tissue, showing significant differences as compared to the saline control group (P < 0.01). The medium- and high-dose luteolin groups significantly reduced the expression of PCNA in H22 hepatoma tissue of ICR mice, where the effect of the high-dose group was the most obvious, and the difference between the two luteolin groups and the normal saline group was statistically significant (P < 0.01). Luteolin may inhibit tumor angiogenesis and tumor cell proliferation by down-regulation of LFA-3 and PCNA and up-regulation of ICAM-1 in tumor tissue of tumor-bearing mice, thereby achieving its anti-tumor effect.

Key words: Luteolin; H22 hepatoma; Tumor tissue; Gene expression

INTRODUCTION

Traditional Chinese medicine theory holds that the pathogenesis of primary liver cancer is the stagnation of qi, blood, damp, heat, stasis, and toxins, which mostly contribute to vital qi deficiency, yin-yang disharmony, disorder of qi and blood, liver qi stagnation, spleen insufficiency, damp retention, phlegm coagulation, and blood stasis; and exogenous pathogenic factors of six climatic conditions in excess for transformation into heat in the course of time and toxic heat accumulation; internal damage by excess of seven emotions and emotional depression (Li et al., 2012; Liao et al., 2012). Luteolin can reduce heat and toxicity, remove jaundice, and eliminate edema, nourishing the liver and relieving pain (Liu et al., 2014). The traditional medicines Rhizoma sparganii, Curcuma zedoary, and Curcuma wenyujin typically enter the liver meridian and can promote the circulation of qi, disrupt blood stasis, remove qi stagnation, and prevent pain (He et al., 2014).

Liver cancer is usually accompanied by the symptoms of spleen-stomach deficiency and indigestion due to retention of food, so the traditional medicines mentioned above are supplemented with dried tangerine peel, Pericarpium citri Reticulatae viride, Coke hawthorn, and baked endothelium corneum gigeriae galli. These additional treatments help to regulate qi-flowing in order to strengthen the spleen, relieve flatulence, and aid transportation and transformation, which can significantly improve clinical symptoms, enhance patients’ quality of life, and prolong survival time (Hsu et al., 2008; Liu et al., 2011). All these medicines enter the spleen meridian. The clinical efficacy of luteolin has been unanimously endorsed by doctors and patients since its clinical application.

In recent years, with the development of molecular biology, cell biology, and genetics, research on the mechanisms of traditional Chinese medicine in the treatment of liver cancer has advanced to the level of gene and cell signal transduction (Li and Ling, 2012; Zhang et al., 2012). A growing number of molecular anti-tumor mechanisms of traditional Chinese medicine have revealed that these medicines may be organically combined according to the targets of action based on syndrome differentiation for treatment using traditional Chinese medicine to improve the therapeutic effects of these medicines on the treatment of liver cancer. Studies have shown that luteolin has a significant tumor-inhibitory effect in mice with H22 hepatoma and S180 sarcoma; however, the exact mechanism is not yet clear (Ouyang et al., 2011). In this study, quantitative PCR was used to evaluate the effect of luteolin on the expression of the ICAM-1, LFA-3, and PCNA in H22 hepatoma tissue of mice and to further explore its molecular mechanism in
order to provide experimental evidence for the clinical application of this medicine.

MATERIAL AND METHODS

Animals and cell line

The H22 hepatoma cell line was purchased from Bio-Rad Life Sciences Development Co., Ltd. (Beijing, China). Specific-pathogem-free Institute of Cancer Research (SPF ICR) mice aged 5 weeks old and weighing 20 ± 1 g were purchased from the Laboratory Animal Science Department of Capital Medical University (Beijing, China), with the certificate No. of conformity of SCXK (Beijing) 2012-0058.

Drugs

Luteolin (ComWin Biotech Co., Ltd., Beijing, China) was prepared as a solution at a concentration of 0.5 g/mL, and then appropriate concentrations were prepared according to the dosage and volume of administration. Cyclophosphamide (CTX) for injection was purchased from Hengrui Medicine Co., Ltd. (Jiangsu, China) lot No. 20120823.

Reagents

TRIzol reagent was purchased from Santa Cruz (CA, USA), and mice ICAM-1, LFA-3, and PCNA fluorescence quantitative RT-PCR detection kits were purchased from Ruixianghe Biotech Co., Ltd. (Beijing, China)

Model establishment, grouping, and administration methods

Sixty ICR male mice, each with a body weight of 20 ± 1 g, were selected. The ascitic fluid of mice that were inoculated with the H22 tumor strain under sterile conditions for 5 days was sampled (the ascitic tumor fluid was thick and ivory in color, yellow or red ascitic fluid was discarded) and diluted with normal saline to adjust the cell concentration to 1 x 10^5/mL. The mice were subcutaneously inoculated in the right axilla of the forelimb with 0.5 mL ascitic tumor fluid for each. After inoculation, the mice were randomly divided into five treatment groups: the normal saline control group, CTX chemotherapy group, low-dose luteolin group, middle-dose luteolin group, and high-dose luteolin group (N = 12 per group). After 24 h of inoculation, the negative control group was intragastrically administrated with 10 mL/kg saline once a day; the positive control group was intraperitoneally injected with 10 mg/kg CTX once a day; and the low-, middle-, and high-dose luteolin groups were intragastrically given 10, 20, and 30 g/kg luteolin solution, respectively, once a day. The administration was withdrawn after 14 days. The mice were euthanized the day after withdrawal and the subcutaneous tumor body was extracted, quickly stored in liquid nitrogen, and then transferred to a low-temperature refrigerator at -35℃ until required.

Quantitative fluorescence RT-PCR

Total mRNA extraction from tumor tissue was undertaken as follows: 1) 100 mg stored tumor tissue was sampled and placed in a 2-mL centrifuge tube with 1 mL TRIzol
for full homogenation, and then left statically at 24°C for 10 min; 2) 0.5 mL chloroform was added, the sample was oscillated for 30 s, and then left to stand statically for 3 min; 3) the sample was centrifuged at 4°C and 3000 rpm for 10 min and the supernatant was extracted; 4) 0.5 mL isopropanol was added and the liquid was mixed in the tube gently and left to stand statically at room temperature for 5 min; 5) the sample was centrifuged at 4°C and 3000 rpm for 10 min and then the supernatant was discarded; 6) 1 mL 75% ethanol was added to gently wash the precipitation and the sample was centrifuged at 4°C and 3000 rpm for 10 min, and then the supernatant was discarded; 7) the sample was air dried and an appropriate amount of DEPC H₂O was added for dissolution (solubilize at 60°C for 5 min). RNA content and purity (OD value at 260 nm) were measured using a UV spectrophotometer and the samples were stored at -35°C until required.

Reverse transcription was performed according to the manufacturer protocol using the following reaction conditions: 37°C for 30 min and 95°C for 2 min. Real-time PCR amplification was conducted according to the manufacturer protocol using the following reaction conditions: 93°C denaturation for 2 min, then 93°C for 30 s and 55°C for 45 s for 30 cycles in total.

The PCR primer sequences are as follows: ICAM-1: forward primer: 5'-AGCGGGGCC CTTACGACATA-3'; reverse primer: 5'-TCACATACGCTCGATAACCCTG-3'; probe primer: 5'-AGCCACCTCATGATGCCCCAGAAG-3'. LFA-3: forward primer: 5'-GGCCAGCTCGAAGCAGCCACGCAGGAC-3'; reverse primer: 5'-CAGGATCCAGGCAGGGCAG-3'; probe primer: 5'-AGT ACCAGAGGTCGCGCGCTC-3'. PCNA: forward primer: 5'-AGCGGACTACCGTATAT A-3'; reverse primer: 5'-GACGACTTGGGACGGAATTGCAAG-3'; probe primer: 5'-TCACCCCTG ACAGCTGGGAATCGAGA-3' (Hou et al., 2010).

Positive standard points were selected for analysis. A correlation coefficient (R²) greater than 0.95 indicated a good linear relationship, which could then be used as a quantitative standard curve. The absolute quantitative values for the quantitative fluorescence reaction of samples could then be obtained according to the standard curve (copy number of cDNA concentration/μL).

Statistical analysis

All data were analyzed using SPSS 14.0. Measurement data are reported as means ± standard deviation, and the differences between groups were analyzed using t-tests.

RESULTS

Effects of luteolin on ICAM-1 mRNA expression in hepatoma tissue

The standard curve of the quantitative fluorescence RT-PCR was:

\[ Y = -3.5183 \log X + 39.6239 \]  

(Equation 1)

R² = 0.9964, which complies with the correlation coefficient of R² > 0.95 in the manufacturer protocol, showing a good linear relationship (Figure 1).
**Figure 1.** Standard curve of ICAM-1 expression in hepatoma tissue from mice.

ICAM-1 expression was the highest in tissue from the middle-dose group, followed by the high-dose group, and the CTX chemotherapy group, successively. Expression of ICAM-1 in the low-dose group and the normal saline control group was similar and the lowest of all groups. ICAM-1 expression was significantly higher in the middle-dose group, the high-dose group, and the CTX chemotherapy group compared to the normal saline control group (P < 0.01; Table 1).

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Dose of saline, CTX, or luteolin</th>
<th>cDNA concentration (copy number/μL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal saline control</td>
<td>10 mL/kg</td>
<td>1362.6 ± 267.5</td>
</tr>
<tr>
<td>Cyclophosphamide (CTX) chemotherapy</td>
<td>10 mg/kg</td>
<td>8539.4 ± 953.8*</td>
</tr>
<tr>
<td>Low-dose luteolin</td>
<td>10 g/kg</td>
<td>1434.8 ± 284.1</td>
</tr>
<tr>
<td>Medium-dose luteolin</td>
<td>10 g/kg</td>
<td>18649.5 ± 1652.6*</td>
</tr>
<tr>
<td>High-dose luteolin</td>
<td>30 g/kg</td>
<td>9928.4 ± 1123.7*</td>
</tr>
</tbody>
</table>

Data are reported as means ± SD. *Significant difference compared to the normal saline control group, P < 0.01.

**Effects of luteolin on LFA-3 mRNA expression in hepatoma tissue**

The standard curve of the quantitative fluorescence RT-PCR was:

\[
Y = -3.2675\log X + 38.6492
\]  

(Equation 2)

R² = 0.9958, which complies with the correlation coefficient R² > 0.95 in the manufacturer protocol, showing a good linear relationship (Figure 2).

The descending order of LFA-3 expression in the treatment groups was as follows: normal saline control group > low-dose group > middle-dose group > CTX treatment group > high-dose group. A significant difference in expression was observed between the low-dose group, the middle-dose group, the high-dose group, and the CTX chemotherapy group compared with the normal saline control group (P < 0.01; Table 2). A significant difference in expression was also observed between the high-dose group and the CTX chemotherapy group (P < 0.01; Table 2).
Effect of luteolin on gene expression in mice

Figure 2. Standard curve of LFA-3 expression in hepatoma tissue from mice.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Dose of saline, CTX, or luteolin</th>
<th>cDNA concentration (copy number/μL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal saline control</td>
<td>10 mL/kg</td>
<td>183545.2 ± 14125.2</td>
</tr>
<tr>
<td>Cyclophosphamide (CTX) chemotherapy</td>
<td>10 mg/kg</td>
<td>15362.9 ± 1683.5*</td>
</tr>
<tr>
<td>Low-dose luteolin</td>
<td>10 g/kg</td>
<td>95365.7 ± 6251.8*</td>
</tr>
<tr>
<td>Medium-dose luteolin</td>
<td>20 g/kg</td>
<td>35418.9 ± 2646.1*</td>
</tr>
<tr>
<td>High-dose luteolin</td>
<td>30 mg/kg</td>
<td>2641.6 ± 396.8*</td>
</tr>
</tbody>
</table>

Data are reported as means ± SD. *Significant difference compared to the normal saline control group, P < 0.01.

Table 2. Quantitative fluorescence RT-PCR results of LFA-3 expression in hepatoma tissue from mice subjected to five treatments.

Effects of luteolin on PCNA mRNA expression in hepatoma tissues

The standard curve of the quantitative fluorescence RT-PCR was:

\[ Y = -3.1686\log(X) + 37.1823 \]  

\( R^2 = 0.9936 \), which complies with the correlation coefficient \( R^2 > 0.95 \) in the manufacturer protocol, showing a good linear relationship (Figure 3).

\( PCNA \) expression was the highest in the normal saline control group, followed by the low-dose and middle-dose groups, and expression in the high-dose group and the CTX chemotherapy group was similar and the lowest of all groups. A significant difference in expression of \( PCNA \) was observed between the high-dose group and the CTX chemotherapy group compared with the normal saline control group (P < 0.01; Table 3), while there was no significant difference in expression between the high-dose group and the CTX chemotherapy group (P > 0.05; Table 3).
Table 3. Quantitative fluorescence RT-PCR results of PCNA expression in hepatoma tissue from mice subjected to five treatments.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Dose of saline, CTX, or luteolin</th>
<th>cDNA concentration (copy number/μL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal saline control</td>
<td>10 mL/kg</td>
<td>15853.9 ± 2511.6</td>
</tr>
<tr>
<td>Cyclophosphamide (CTX) chemotherapy</td>
<td>10 mg/kg</td>
<td>13364.8 ± 1738.4</td>
</tr>
<tr>
<td>Low-dose luteolin</td>
<td>10 g/kg</td>
<td>9824.5 ± 1251.4*</td>
</tr>
<tr>
<td>Medium-dose luteolin</td>
<td>20 g/kg</td>
<td>3962.8 ± 625.5*</td>
</tr>
<tr>
<td>High-dose luteolin</td>
<td>30 g/kg</td>
<td>3748.1 ± 568.8*</td>
</tr>
</tbody>
</table>

Data are reported as means ± SD. *Significant difference compared to the normal saline control group, P < 0.01.

DISCUSSION

With the use of genomic and proteomic technologies in the early detection, postoperative recurrence, metastasis monitoring, positive high sensitivity, and specific diagnosis of liver cancer, it has been found that the progress of liver cancer is closely correlated with the over-expression of a variety of growth factors, such as ICAM-1, LFA-3, and PCNA in liver tissue, which has complex molecular mechanisms (Kawai et al., 2009; Ueda et al., 2009). Experimental studies have shown that luteolin has a significant tumor-inhibitory effect in mice with H22 hepatoma and S180 sarcoma. Low-, medium- and high-dose luteolin groups can all prolong the survival days of mice with H22 hepatoma ascetic tumor and can down-regulate the expression of CyclinD1 mRNA in tumor tissue (Pan et al., 2012). The current study further examined the effect of luteolin on the expression of the ICAM-1, LFA-3, and PCNA in tumor tissue of mice with H22 hepatoma.

ICAM is a multifunctional cytokine, involved in the process of cell cycle regulation, wound healing, angiogenesis, cell growth, differentiation, apoptosis, etc. (Tse et al., 2009). ICAM-1 can play a tumor suppressor role by inhibiting cell growth and promoting differentiation, and activated ICAM-1 functions through the mediation of its corresponding receptor (Turner et al., 2011). Recent studies suggest that decreased expression of the transforming growth factor ICAM-1 is an important alteration in the negative growth regulation of tumor
cells escaping from immune surveillance, which may lead to uncontrolled proliferation and
canceration (Zapolska-Downar and Naruszewicz, 2009). Studies have found that, compared to
hepatitis or liver fibrosis patients, expression of ICAM-1 in patients with liver cancer is signifi-
cantly reduced, and ICAM-1 expression in hepatoma tissue is also significantly lower than that
of normal tissue, while ICAM-1 expression is higher in hepatoma tissue with high differentation,
small tumor size, low metastasis, and long recurrence interval (P < 0.05) (Rizk and Derbala,
2013). This indicates that ICAM-1 expression is reduced in hepatoma tissue, leading to a nega-
tive regulatory barrier of liver cancer cells, which may be one of the key factors for hepatocellu-
lar canceration. ICAM-1 expression, which is negatively correlated with the malignant progres-
sion of liver cancer, has potential significance in the treatment of this disease (Tu et al., 2011).

The nuclear transcription factor LFA-3 can participate in many stages in the occurrence
and development of liver cancer, such as blocking gene expression related to apoptosis, promoting
cell proliferation, mediating tumor development, angiogenesis and metastasis, promoting tumor
cell invasion and spreading, as well as the generation of tumor drug-resistance, and it is also a major
regulatory factor of LFA synthesis (Metzler et al., 2008). Studies have found that LFA-3 exhibited
significantly higher expression in hepatoma tissue, suggesting that LFA-3 may play the role of on-
cogene in the occurrence and development of liver cancer (Franciszkiewicz et al., 2013).

PCNA, as a major pro-angiogenic factor in tumor tissue, can directly stimulate the pro-
liferation of endothelial cells through specific receptors, stimulating production of plasminogen
activator and collagenase, and increasing vascular permeability and promoting plasma fibrin
exosmosis (Bologna-Molina et al., 2013). This not only promotes endothelial cell migration,
which is conducive to angiogenesis, but also helps tumor cells shed into blood vessels or diffuse
to matrices near fibrous and connective tissues, so as to create the conditions for tumor invasion
and metastasis. Liver cancer is a malignancy with rich blood supply and high metastasis, and
PCNA is closely related with tumor angiogenesis, proliferation, invasion, and metastasis (Mar-
gotta, 2012). Studies have shown that the expression rates of PCNA in liver cancer, nonencaps-
sulated liver cancer, and liver cancer with extrahepatic metastasis were 63.9, 78.3, and 90.9%,
respectively. Under high expression of PCNA, hepatoma tissue can produce a large number of
tumor blood vessels; at the same time, PCNA can also increase capillary permeability, thereby
enabling tumor blood perfusion to be increased (Lee and Lim, 2009). The results of the current
study show that each luteolin dose group up-regulates ICAM-1 expression and down-regulates
the expression of LFA-3 and PCNA. This suggests that the tumor-inhibitory effect of luteolin
is multi-channeled and multi-targeted, which not only affects the cycle-regulatory factors of
tumor cells, but also inhibits tumor angiogenesis and tumor cell proliferation by regulating
relevant vascular factors, ultimately achieving its anti-tumor effect. The in-depth mechanism
of the tumor-inhibitory effect of luteolin needs to be further studied, while the results of this
investigation provide experimental basis for the clinical application of this medicine.

Conflicts of interest

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

Research supported by the One Million Technology Project of Inner Mongolia Medi-
cal University (#NY2011bw004), the Medical and Health Research Project of Health Bureau

of Inner Mongolia (#2010038), the Doctoral Station Initiation Project of Inner Mongolia Medical University (#Nyfybz2010003), and the Scientific Research Project of the Higher Education Institutions of Inner Mongolia Autonomous Region (#NJZY13416).

REFERENCES


